^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Thymidine phosphorylase inhibitor

    Related drugs:
    2d
    Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial (clinicaltrials.gov)
    P2, N=236, Not yet recruiting, Sun Yat-sen University
    New P2 trial • Head-to-Head
    |
    Avastin (bevacizumab) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    11d
    A Sequential Triple-Drug Strategy for Selective Targeting of p53-Mutant Cancers. (PubMed, bioRxiv)
    Here we show that a combination of a thymidine analogue (TAS102) plus PARP inhibitor (PARPi) promotes formation of DNA double-strand breaks (DSBs) and G2-arrest specifically in p53 mutant cancer cells...This sequential triple-drug strategy exhibited robust efficacy in preclinical models of colorectal and pancreatic cancers and was well tolerated in mice. Together, our findings illustrate a promising triple-drug strategy for targeting p53 mutant malignancies.
    Journal • PARP Biomarker • P53mut
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type
    |
    Lonsurf (trifluridine/tipiracil)
    13d
    CombiCoR-Vax trial: study protocol for a phase II, single-arm, multicenter trial of sequential pembrolizumab plus dendritic cell vaccine followed by trifluridine/tipiracil and bevacizumab in refractory microsatellite-stable metastatic colorectal cancer. (PubMed, BMC Cancer)
    This study explores a novel sequential immunochemotherapy approach combining a DC-based vaccine with anti-PD-1 immunotherapy and standard chemotherapy in patients with refractory pMMR/MSS mCRC. By integrating cellular immunotherapy without omitting the current standard of care (FTD/TPI plus bevacizumab), the trial aims to enhance treatment efficacy in a setting traditionally resistant to immunological strategies. To the best of our knowledge, this is the only ongoing trial investigating this therapeutic combination in this specific patient population.
    P2 data • Journal
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)
    22d
    Interventional Radiotherapy (Brachytherapy) Combined with Systemic Treatment-The Influence of RAS Gene Mutations and Combined Therapy on the Results and Toxicity of Colorectal Cancer Liver Metastases. (PubMed, Cancers (Basel))
    A mutation in the RAS genes worsens the prognosis, regardless of the line of treatment and the systemic treatment used. The greatest benefit from brachytherapy is seen in patients in the first three lines of treatment without RAS mutations, treated with anti-EGFR chemotherapy in the first line and trifluridine/tipiracil in the third line. Combining brachytherapy of liver metastases with systemic treatment is safe, regardless of the systemic treatment used.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation • RAS mutation
    |
    Lonsurf (trifluridine/tipiracil)
    23d
    Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=27, Recruiting, Case Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    oxaliplatin • Lonsurf (trifluridine/tipiracil)
    1m
    TAS-102 NEC: TAS-102 in Extrapulmonary Neuroendocrine Carcinoma (clinicaltrials.gov)
    P2, N=14, Terminated, Baylor Research Institute | Trial completion date: Aug 2023 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Aug 2023 --> Sep 2025; Study halted due to low enrollment
    Trial completion date • Trial termination • Trial primary completion date
    |
    Lonsurf (trifluridine/tipiracil)
    1m
    Fruquintinib in combination with TAS-102 versus bevacizumab in combination with TAS-102 in the third line and later for the treatment of advanced metastatic CRC Non-randomized controlled, single-center, retrospective, cohort study (ChiCTR2500110400)
    P=N/A, N=80, Recruiting, Ningbo No.2 Hospital; Ningbo No.2 Hospital
    New trial
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    Avastin (bevacizumab) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    1m
    Hypofractionated Radiotherapy Followed by Sequential Ipalolimab-Toripalimab Combined with Trifluridine-Tipiracil and Bevacizumab as Third-Line Treatment for Metastatic Colorectal Cancer: A Phase II Prospective, Single-Arm, Single-Center Clinical Study on Efficacy and Safety (ChiCTR2500107958)
    P=N/A, N=32, Not yet recruiting, Jiangxi Cancer Hospital; Jiangxi Cancer Hospital
    New trial
    |
    Avastin (bevacizumab) • Loqtorzi (toripalimab-tpzi) • Lonsurf (trifluridine/tipiracil)
    1m
    FIERCE: TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, OHSU Knight Cancer Institute | Trial completion date: May 2025 --> May 2026
    Trial completion date
    |
    Lonsurf (trifluridine/tipiracil)
    2ms
    RAK in GC: The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial (clinicaltrials.gov)
    P2, N=90, Recruiting, Chinese PLA General Hospital
    New P2 trial
    |
    Lonsurf (trifluridine/tipiracil)